Cargando…
Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive brain disease characterised by progressive memory loss and cognition impairment, ultimately leading to death. There are three FDA-approved acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine, AChEIs) for the symptomatic treatment of AD....
Autores principales: | Zou, Dajiang, Liu, Renzheng, Lv, Yangjing, Guo, Jianan, Zhang, Changjun, Xie, Yuanyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653629/ https://www.ncbi.nlm.nih.gov/pubmed/37955252 http://dx.doi.org/10.1080/14756366.2023.2270781 |
Ejemplares similares
-
Chromone-based monoamine oxidase B inhibitor with potential iron-chelating activity for the treatment of Alzheimer’s disease
por: Zhang, Changjun, et al.
Publicado: (2022) -
Dual Reversible Coumarin Inhibitors Mutually Bound
to Monoamine Oxidase B and Acetylcholinesterase Crystal Structures
por: Ekström, Fredrik, et al.
Publicado: (2022) -
Dual-target anti-Alzheimer’s disease agents with both iron ion chelating and monoamine oxidase-B inhibitory activity
por: Mi, Zhisheng, et al.
Publicado: (2019) -
Morpholine-based chalcones as dual-acting monoamine oxidase-B and acetylcholinesterase inhibitors: synthesis and biochemical investigations
por: Sasidharan, Rani, et al.
Publicado: (2021) -
Novel Class of Chalcone Oxime Ethers as Potent Monoamine Oxidase-B and Acetylcholinesterase Inhibitors
por: Oh, Jong Min, et al.
Publicado: (2020)